Abstract 317P
Background
Molecular characteristics are essential for the classification and grading of glioma. However, the majority of current understanding is based on public databases that might not accurately reflect the Asian population. Here, we studied the genetic landscape of Chinese glioma patients in hope to provide strong rationales for future molecular classification and prognosis of glioma.
Methods
Tissue samples from 81 glioma patients of which 21 (26%) were astrocytoma (A) and oligodendroglioma (O), 16 (20%) were anaplastic astrocytoma/oligodendroglioma (AO/AA), 32 (40%) were Glioblastoma (GBM), and 8 (10%) were diffuse midline glioma underwent next-generation sequencing with Acornmed panel including 808 cancer-relevant genes.
Results
We identified currently established molecular pathologic markers of glioma, including TP53 (41%),TERT (34%), IDH1/2 (30%), PTEN (19%), ATRX (18%), EGFR (16%), H3F3A (10%) and BRAF (6%). IDH mutations were frequent in A and O and were a major discriminate of biologic class (P=0.002). IDH-mutant A/O (grades II) were characterized by MGMT methylation, ATRX, and CIC mutations. AO/AA (grades III) were also IDH1/2-mutant, but instead are characterized by TP53, BRAF, and FUBP1 mutations. GBM typically lacked IDH1/2 mutations and demonstrated EGFR, PTEN, TP53, PIK3CA, and CDKN2A alterations, and TERT promoter mutations. Copy number variations as EGFR, PDGFRA, MET, KIT, which were also significantly associated with GBM but not used for clinical classification (P=0.001). Clinically actionable genetic alterations were detected in 80.95%, 81.25%, and 93.75% of A/O, AA/AO, and GBM, respectively.
Conclusions
We demonstrate that genes characterize the distinction between these pathologic subsets. These results further define molecular subsets of gliomas which may potentially be used for patient stratification and suggest potential targets for treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
M. Li, H. Cheng, H. Wang, S. Cao: Full/Part-time employment: Beijing Acornmed Biotechnology Co., Ltd. All other authors have declared no conflicts of interest.
Resources from the same session
434P - Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?
Presenter: Kiran Virik
Session: e-Poster Display Session
435P - Hypnotics and risk of cancer: A meta-analysis of observational studies
Presenter: Tzu Rong Peng
Session: e-Poster Display Session
436P - Clinicopathological characteristics and outcomes of adolescent and young adult (AYA) melanoma: Results from an Asian perspective
Presenter: Wei Lin Goh
Session: e-Poster Display Session
437P - Long-term efficacy and toxicity outcome of adjuvant external beam radiotherapy for medullary thyroid cancer: A single institution cohort study
Presenter: Ka Man Cheung
Session: e-Poster Display Session
438P - Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma
Presenter: Carolina Ortiz Velez
Session: e-Poster Display Session
439P - Immunohistochemical analysis of p53 and Ki-67 in glioblastoma (GBM) and their correlations with patient survival
Presenter: Paulo Luz
Session: e-Poster Display Session
440P - Blinded independent central review of oncology trials: The monitoring of readers' performance
Presenter: Hubert Beaumont
Session: e-Poster Display Session
441P - Influence of radiation therapy of patients with somatotropic pituitary adenomas depending on the age of patients
Presenter: Saodat Issaeva
Session: e-Poster Display Session
442P - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)
Presenter: Bhumsuk Keam
Session: e-Poster Display Session